Establishment Labs Holdings Inc

Although the medium-term remains bullish in a Stage 2 advancing regime, the active Bullish Exhaustion candle and overbought context suggest near-term pullback risk. Execution should be deferred until price stabilizes and pulls back into rising EMAs or prior support zones. Monitoring for absorption around the 20 EMA and 50 DMA will define the next favorable entry opportunity.

• ↑Q1 revenue $59.9M (+45% YoY); US sales +216% to $19.6M
• ↑Adjusted EBITDA of $1.2M with 70.7% gross margin and $68.1M cash
• ↓Elevated debt levels raise refinancing and downturn vulnerability